A human immunodeficiency virus type 1 (HIV-1) mutant lacking the V1 and V2 variable loops in the gp120 exterior envelope glycoprotein replicated in Jurkat lymphocytes with only modest delays compared with the wild-type virus. Revertants that replicated with wild-type efficiency rapidly emerged and contained only a few amino acid changes in the envelope glycoproteins compared with the parent virus. Both the parent and revertant viruses exhibited increased sensitivity to neutralization by antibodies directed against the V3 loop or a CD4-induced epitope on gp120 but not by soluble CD4 or an antibody against the CD4 binding site. This result demonstrates the role of the gp120 V1 and V2 loops in protecting HIV-1 from some subsets of neutralizing...
AbstractA conserved N-glycan present within the V3 loop of gp120 modulates the sensitivity to neutra...
Vaccines prepared from the envelope glycoprotein, gpl20, of the common laboratory isolate of human i...
Using recombinant and mutant viruses generated between two human immunodeficiency virus type 1 isola...
A human immunodeficiency virus type 1 (HIV-1) mutant lacking the V1 and V2 variable loops in the gp1...
The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potent...
Neutralizing antibodies often recognize regions of viral envelope glycoproteins that play a role in ...
AbstractIt has been extremely difficult to elicit broadly cross-reactive neutralizing antibodies (Na...
The envelope glycoproteins of HIV, gp120 and gp41, contain epitopes recognized by neutralizing antib...
Human immunodeficiency virus type 1 (HIV-1) has the ability to adapt to the host environment by esca...
The major target of the neutralizing antibody response to infection by the human immunodeficiency vi...
By comparing HIV-1 variants from people who became infected at the beginning of the epidemic and fro...
AbstractDifferent isolates of HIV-1 are known to vary in antibody binding and sensitivity to neutral...
<div><p>Understanding the molecular determinants of sensitivity and resistance to neutralizing antib...
AbstractWe constructed a number of HXB2 viruses chimeric for the gp120 glycoprotein derived from a n...
glycoprotein. and V2 variable loops of the gp120 envelope immunodeficiency virus type 1 lacking the ...
AbstractA conserved N-glycan present within the V3 loop of gp120 modulates the sensitivity to neutra...
Vaccines prepared from the envelope glycoprotein, gpl20, of the common laboratory isolate of human i...
Using recombinant and mutant viruses generated between two human immunodeficiency virus type 1 isola...
A human immunodeficiency virus type 1 (HIV-1) mutant lacking the V1 and V2 variable loops in the gp1...
The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potent...
Neutralizing antibodies often recognize regions of viral envelope glycoproteins that play a role in ...
AbstractIt has been extremely difficult to elicit broadly cross-reactive neutralizing antibodies (Na...
The envelope glycoproteins of HIV, gp120 and gp41, contain epitopes recognized by neutralizing antib...
Human immunodeficiency virus type 1 (HIV-1) has the ability to adapt to the host environment by esca...
The major target of the neutralizing antibody response to infection by the human immunodeficiency vi...
By comparing HIV-1 variants from people who became infected at the beginning of the epidemic and fro...
AbstractDifferent isolates of HIV-1 are known to vary in antibody binding and sensitivity to neutral...
<div><p>Understanding the molecular determinants of sensitivity and resistance to neutralizing antib...
AbstractWe constructed a number of HXB2 viruses chimeric for the gp120 glycoprotein derived from a n...
glycoprotein. and V2 variable loops of the gp120 envelope immunodeficiency virus type 1 lacking the ...
AbstractA conserved N-glycan present within the V3 loop of gp120 modulates the sensitivity to neutra...
Vaccines prepared from the envelope glycoprotein, gpl20, of the common laboratory isolate of human i...
Using recombinant and mutant viruses generated between two human immunodeficiency virus type 1 isola...